nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxepin—CYP2D6—Hydroxyurea—head and neck cancer	0.113	0.3	CbGbCtD
Doxepin—CYP1A2—Fluorouracil—head and neck cancer	0.0526	0.139	CbGbCtD
Doxepin—CYP2C9—Fluorouracil—head and neck cancer	0.0474	0.125	CbGbCtD
Doxepin—ABCB1—Vinblastine—head and neck cancer	0.0426	0.113	CbGbCtD
Doxepin—CYP2D6—Vinblastine—head and neck cancer	0.0401	0.106	CbGbCtD
Doxepin—ABCB1—Docetaxel—head and neck cancer	0.0351	0.0929	CbGbCtD
Doxepin—CYP3A4—Vinblastine—head and neck cancer	0.0255	0.0676	CbGbCtD
Doxepin—CYP3A4—Docetaxel—head and neck cancer	0.021	0.0557	CbGbCtD
Doxepin—Sensory loss—Vinblastine—head and neck cancer	0.00482	0.012	CcSEcCtD
Doxepin—Lacrimation—Fluorouracil—head and neck cancer	0.00466	0.0116	CcSEcCtD
Doxepin—HRH1—nose—head and neck cancer	0.00431	0.102	CbGeAlD
Doxepin—ORM1—saliva—head and neck cancer	0.00397	0.0938	CbGeAlD
Doxepin—Neoplasm—Vinblastine—head and neck cancer	0.00377	0.00943	CcSEcCtD
Doxepin—Menstruation irregular—Docetaxel—head and neck cancer	0.00357	0.00892	CcSEcCtD
Doxepin—Neoplasm—Hydroxyurea—head and neck cancer	0.00344	0.0086	CcSEcCtD
Doxepin—Tingling sensation—Fluorouracil—head and neck cancer	0.00341	0.00851	CcSEcCtD
Doxepin—Deafness—Vinblastine—head and neck cancer	0.00339	0.00846	CcSEcCtD
Doxepin—Stinging—Fluorouracil—head and neck cancer	0.00338	0.00845	CcSEcCtD
Doxepin—Lacrimation—Docetaxel—head and neck cancer	0.00336	0.0084	CcSEcCtD
Doxepin—Numbness—Fluorouracil—head and neck cancer	0.0033	0.00826	CcSEcCtD
Doxepin—Polyp—Docetaxel—head and neck cancer	0.00325	0.00812	CcSEcCtD
Doxepin—Sensory loss—Fluorouracil—head and neck cancer	0.00316	0.0079	CcSEcCtD
Doxepin—Cerebrovascular accident—Vinblastine—head and neck cancer	0.00309	0.00772	CcSEcCtD
Doxepin—Disorientation—Hydroxyurea—head and neck cancer	0.00309	0.00772	CcSEcCtD
Doxepin—Lacrimation increased—Fluorouracil—head and neck cancer	0.00297	0.00743	CcSEcCtD
Doxepin—Cyst—Docetaxel—head and neck cancer	0.00296	0.00739	CcSEcCtD
Doxepin—Pharyngolaryngeal pain—Docetaxel—head and neck cancer	0.00293	0.00732	CcSEcCtD
Doxepin—Laryngeal pain—Docetaxel—head and neck cancer	0.0029	0.00725	CcSEcCtD
Doxepin—HTR2A—trigeminal nerve—head and neck cancer	0.00282	0.0667	CbGeAlD
Doxepin—Dermatitis contact—Fluorouracil—head and neck cancer	0.00271	0.00676	CcSEcCtD
Doxepin—Breast disorder—Hydroxyurea—head and neck cancer	0.0025	0.00624	CcSEcCtD
Doxepin—Pancytopenia—Vinblastine—head and neck cancer	0.00249	0.00621	CcSEcCtD
Doxepin—Rhinorrhoea—Docetaxel—head and neck cancer	0.00244	0.0061	CcSEcCtD
Doxepin—Ageusia—Docetaxel—head and neck cancer	0.00244	0.0061	CcSEcCtD
Doxepin—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00229	0.00572	CcSEcCtD
Doxepin—Pancytopenia—Hydroxyurea—head and neck cancer	0.00227	0.00567	CcSEcCtD
Doxepin—Dysuria—Hydroxyurea—head and neck cancer	0.00223	0.00558	CcSEcCtD
Doxepin—Disorientation—Fluorouracil—head and neck cancer	0.00222	0.00555	CcSEcCtD
Doxepin—Agranulocytosis—Vinblastine—head and neck cancer	0.00218	0.00544	CcSEcCtD
Doxepin—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00217	0.00543	CcSEcCtD
Doxepin—Weight increased—Hydroxyurea—head and neck cancer	0.00217	0.00543	CcSEcCtD
Doxepin—Lacrimation increased—Docetaxel—head and neck cancer	0.00214	0.00536	CcSEcCtD
Doxepin—Drowsiness—Hydroxyurea—head and neck cancer	0.00213	0.00532	CcSEcCtD
Doxepin—Infestation NOS—Hydroxyurea—head and neck cancer	0.00213	0.00532	CcSEcCtD
Doxepin—Infestation—Hydroxyurea—head and neck cancer	0.00213	0.00532	CcSEcCtD
Doxepin—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00209	0.00521	CcSEcCtD
Doxepin—Hypoaesthesia—Vinblastine—head and neck cancer	0.00208	0.00521	CcSEcCtD
Doxepin—Pharyngitis—Vinblastine—head and neck cancer	0.00208	0.0052	CcSEcCtD
Doxepin—Hearing impaired—Docetaxel—head and neck cancer	0.00208	0.00519	CcSEcCtD
Doxepin—Stomatitis—Hydroxyurea—head and neck cancer	0.00207	0.00518	CcSEcCtD
Doxepin—Lethargy—Fluorouracil—head and neck cancer	0.00203	0.00507	CcSEcCtD
Doxepin—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00201	0.00503	CcSEcCtD
Doxepin—HTR2A—cranial nerve—head and neck cancer	0.00201	0.0475	CbGeAlD
Doxepin—Blood pressure increased—Docetaxel—head and neck cancer	0.00198	0.00494	CcSEcCtD
Doxepin—Hallucination—Hydroxyurea—head and neck cancer	0.0019	0.00475	CcSEcCtD
Doxepin—Ataxia—Fluorouracil—head and neck cancer	0.00187	0.00467	CcSEcCtD
Doxepin—Alopecia—Vinblastine—head and neck cancer	0.00185	0.00463	CcSEcCtD
Doxepin—Neoplasm—Docetaxel—head and neck cancer	0.00179	0.00447	CcSEcCtD
Doxepin—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00178	0.00444	CcSEcCtD
Doxepin—Angiopathy—Hydroxyurea—head and neck cancer	0.00173	0.00433	CcSEcCtD
Doxepin—Chills—Hydroxyurea—head and neck cancer	0.00171	0.00428	CcSEcCtD
Doxepin—Eosinophilia—Fluorouracil—head and neck cancer	0.0017	0.00425	CcSEcCtD
Doxepin—Ill-defined disorder—Vinblastine—head and neck cancer	0.00169	0.00423	CcSEcCtD
Doxepin—Alopecia—Hydroxyurea—head and neck cancer	0.00169	0.00422	CcSEcCtD
Doxepin—Anaemia—Vinblastine—head and neck cancer	0.00169	0.00421	CcSEcCtD
Doxepin—Erythema—Hydroxyurea—head and neck cancer	0.00166	0.00416	CcSEcCtD
Doxepin—Malaise—Vinblastine—head and neck cancer	0.00164	0.00411	CcSEcCtD
Doxepin—Vertigo—Vinblastine—head and neck cancer	0.00164	0.00409	CcSEcCtD
Doxepin—Leukopenia—Vinblastine—head and neck cancer	0.00163	0.00408	CcSEcCtD
Doxepin—Pancytopenia—Fluorouracil—head and neck cancer	0.00163	0.00408	CcSEcCtD
Doxepin—Deafness—Docetaxel—head and neck cancer	0.0016	0.00401	CcSEcCtD
Doxepin—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.0016	0.00399	CcSEcCtD
Doxepin—Convulsion—Vinblastine—head and neck cancer	0.00158	0.00395	CcSEcCtD
Doxepin—Hypertension—Vinblastine—head and neck cancer	0.00157	0.00393	CcSEcCtD
Doxepin—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00154	0.00386	CcSEcCtD
Doxepin—Pneumonia—Fluorouracil—head and neck cancer	0.00154	0.00385	CcSEcCtD
Doxepin—Anaemia—Hydroxyurea—head and neck cancer	0.00154	0.00384	CcSEcCtD
Doxepin—Discomfort—Vinblastine—head and neck cancer	0.00153	0.00383	CcSEcCtD
Doxepin—Hot flush—Docetaxel—head and neck cancer	0.00153	0.00383	CcSEcCtD
Doxepin—Infestation NOS—Fluorouracil—head and neck cancer	0.00153	0.00383	CcSEcCtD
Doxepin—Infestation—Fluorouracil—head and neck cancer	0.00153	0.00383	CcSEcCtD
Doxepin—CHRM3—exocrine gland—head and neck cancer	0.00153	0.036	CbGeAlD
Doxepin—Menopausal symptoms—Docetaxel—head and neck cancer	0.00152	0.0038	CcSEcCtD
Doxepin—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.0015	0.00375	CcSEcCtD
Doxepin—Malaise—Hydroxyurea—head and neck cancer	0.0015	0.00375	CcSEcCtD
Doxepin—Stomatitis—Fluorouracil—head and neck cancer	0.00149	0.00373	CcSEcCtD
Doxepin—Urinary tract infection—Fluorouracil—head and neck cancer	0.00149	0.00372	CcSEcCtD
Doxepin—Leukopenia—Hydroxyurea—head and neck cancer	0.00149	0.00372	CcSEcCtD
Doxepin—Lethargy—Docetaxel—head and neck cancer	0.00146	0.00366	CcSEcCtD
Doxepin—Thrombocytopenia—Vinblastine—head and neck cancer	0.00146	0.00364	CcSEcCtD
Doxepin—Convulsion—Hydroxyurea—head and neck cancer	0.00144	0.0036	CcSEcCtD
Doxepin—Sinusitis—Fluorouracil—head and neck cancer	0.00144	0.00359	CcSEcCtD
Doxepin—Pain in extremity—Docetaxel—head and neck cancer	0.00143	0.00359	CcSEcCtD
Doxepin—Agranulocytosis—Fluorouracil—head and neck cancer	0.00143	0.00357	CcSEcCtD
Doxepin—Anorexia—Vinblastine—head and neck cancer	0.00142	0.00355	CcSEcCtD
Doxepin—Migraine—Docetaxel—head and neck cancer	0.00141	0.00353	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00141	0.00351	CcSEcCtD
Doxepin—Discomfort—Hydroxyurea—head and neck cancer	0.0014	0.0035	CcSEcCtD
Doxepin—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00137	0.00342	CcSEcCtD
Doxepin—Pharyngitis—Fluorouracil—head and neck cancer	0.00136	0.00341	CcSEcCtD
Doxepin—Oedema—Hydroxyurea—head and neck cancer	0.00136	0.00339	CcSEcCtD
Doxepin—Ataxia—Docetaxel—head and neck cancer	0.00135	0.00337	CcSEcCtD
Doxepin—Infection—Hydroxyurea—head and neck cancer	0.00135	0.00337	CcSEcCtD
Doxepin—Paraesthesia—Vinblastine—head and neck cancer	0.00134	0.00334	CcSEcCtD
Doxepin—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00133	0.00333	CcSEcCtD
Doxepin—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00133	0.00332	CcSEcCtD
Doxepin—Skin disorder—Hydroxyurea—head and neck cancer	0.00132	0.00329	CcSEcCtD
Doxepin—Breast disorder—Docetaxel—head and neck cancer	0.0013	0.00324	CcSEcCtD
Doxepin—Anorexia—Hydroxyurea—head and neck cancer	0.00129	0.00323	CcSEcCtD
Doxepin—Decreased appetite—Vinblastine—head and neck cancer	0.00129	0.00323	CcSEcCtD
Doxepin—Cramp muscle—Docetaxel—head and neck cancer	0.00129	0.00323	CcSEcCtD
Doxepin—Nasopharyngitis—Docetaxel—head and neck cancer	0.00128	0.00321	CcSEcCtD
Doxepin—Constipation—Vinblastine—head and neck cancer	0.00127	0.00318	CcSEcCtD
Doxepin—Pain—Vinblastine—head and neck cancer	0.00127	0.00318	CcSEcCtD
Doxepin—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00127	0.00316	CcSEcCtD
Doxepin—Arrhythmia—Fluorouracil—head and neck cancer	0.00123	0.00307	CcSEcCtD
Doxepin—Feeling abnormal—Vinblastine—head and neck cancer	0.00123	0.00307	CcSEcCtD
Doxepin—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00122	0.00304	CcSEcCtD
Doxepin—Alopecia—Fluorouracil—head and neck cancer	0.00122	0.00304	CcSEcCtD
Doxepin—Dyspnoea—Hydroxyurea—head and neck cancer	0.00121	0.00302	CcSEcCtD
Doxepin—Somnolence—Hydroxyurea—head and neck cancer	0.00121	0.00302	CcSEcCtD
Doxepin—Erythema—Fluorouracil—head and neck cancer	0.0012	0.00299	CcSEcCtD
Doxepin—Dyspepsia—Hydroxyurea—head and neck cancer	0.00119	0.00299	CcSEcCtD
Doxepin—CHRM5—epithelium—head and neck cancer	0.00119	0.028	CbGeAlD
Doxepin—Decreased appetite—Hydroxyurea—head and neck cancer	0.00118	0.00295	CcSEcCtD
Doxepin—Pancytopenia—Docetaxel—head and neck cancer	0.00118	0.00294	CcSEcCtD
Doxepin—Abdominal pain—Vinblastine—head and neck cancer	0.00118	0.00294	CcSEcCtD
Doxepin—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00117	0.00293	CcSEcCtD
Doxepin—Fatigue—Hydroxyurea—head and neck cancer	0.00117	0.00292	CcSEcCtD
Doxepin—Constipation—Hydroxyurea—head and neck cancer	0.00116	0.0029	CcSEcCtD
Doxepin—Pain—Hydroxyurea—head and neck cancer	0.00116	0.0029	CcSEcCtD
Doxepin—Weight increased—Docetaxel—head and neck cancer	0.00113	0.00282	CcSEcCtD
Doxepin—Vision blurred—Fluorouracil—head and neck cancer	0.00113	0.00282	CcSEcCtD
Doxepin—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00112	0.0028	CcSEcCtD
Doxepin—Pneumonia—Docetaxel—head and neck cancer	0.00111	0.00278	CcSEcCtD
Doxepin—Anaemia—Fluorouracil—head and neck cancer	0.00111	0.00277	CcSEcCtD
Doxepin—Infestation NOS—Docetaxel—head and neck cancer	0.00111	0.00276	CcSEcCtD
Doxepin—Infestation—Docetaxel—head and neck cancer	0.00111	0.00276	CcSEcCtD
Doxepin—Hypersensitivity—Vinblastine—head and neck cancer	0.0011	0.00274	CcSEcCtD
Doxepin—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00108	0.00271	CcSEcCtD
Doxepin—Stomatitis—Docetaxel—head and neck cancer	0.00108	0.00269	CcSEcCtD
Doxepin—Jaundice—Docetaxel—head and neck cancer	0.00108	0.00269	CcSEcCtD
Doxepin—Body temperature increased—Hydroxyurea—head and neck cancer	0.00107	0.00268	CcSEcCtD
Doxepin—Leukopenia—Fluorouracil—head and neck cancer	0.00107	0.00268	CcSEcCtD
Doxepin—Asthenia—Vinblastine—head and neck cancer	0.00107	0.00267	CcSEcCtD
Doxepin—ADRA1D—epithelium—head and neck cancer	0.00106	0.0251	CbGeAlD
Doxepin—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00105	0.00261	CcSEcCtD
Doxepin—Convulsion—Fluorouracil—head and neck cancer	0.00104	0.00259	CcSEcCtD
Doxepin—Agranulocytosis—Docetaxel—head and neck cancer	0.00103	0.00258	CcSEcCtD
Doxepin—Chest pain—Fluorouracil—head and neck cancer	0.00102	0.00255	CcSEcCtD
Doxepin—Myalgia—Fluorouracil—head and neck cancer	0.00102	0.00255	CcSEcCtD
Doxepin—Diarrhoea—Vinblastine—head and neck cancer	0.00102	0.00255	CcSEcCtD
Doxepin—Discomfort—Fluorouracil—head and neck cancer	0.00101	0.00252	CcSEcCtD
Doxepin—Hypersensitivity—Hydroxyurea—head and neck cancer	0.001	0.0025	CcSEcCtD
Doxepin—Hepatitis—Docetaxel—head and neck cancer	0.000993	0.00248	CcSEcCtD
Doxepin—Hypoaesthesia—Docetaxel—head and neck cancer	0.000988	0.00247	CcSEcCtD
Doxepin—Confusional state—Fluorouracil—head and neck cancer	0.000985	0.00246	CcSEcCtD
Doxepin—Pharyngitis—Docetaxel—head and neck cancer	0.000985	0.00246	CcSEcCtD
Doxepin—Dizziness—Vinblastine—head and neck cancer	0.000984	0.00246	CcSEcCtD
Doxepin—Urinary tract disorder—Docetaxel—head and neck cancer	0.00098	0.00245	CcSEcCtD
Doxepin—Oedema peripheral—Docetaxel—head and neck cancer	0.000978	0.00244	CcSEcCtD
Doxepin—Oedema—Fluorouracil—head and neck cancer	0.000977	0.00244	CcSEcCtD
Doxepin—Connective tissue disorder—Docetaxel—head and neck cancer	0.000975	0.00244	CcSEcCtD
Doxepin—Asthenia—Hydroxyurea—head and neck cancer	0.000974	0.00243	CcSEcCtD
Doxepin—Urethral disorder—Docetaxel—head and neck cancer	0.000973	0.00243	CcSEcCtD
Doxepin—Infection—Fluorouracil—head and neck cancer	0.000971	0.00243	CcSEcCtD
Doxepin—Nervous system disorder—Fluorouracil—head and neck cancer	0.000958	0.00239	CcSEcCtD
Doxepin—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000957	0.00239	CcSEcCtD
Doxepin—Tachycardia—Fluorouracil—head and neck cancer	0.000954	0.00238	CcSEcCtD
Doxepin—Vomiting—Vinblastine—head and neck cancer	0.000946	0.00237	CcSEcCtD
Doxepin—CHRM4—head—head and neck cancer	0.000943	0.0223	CbGeAlD
Doxepin—Headache—Vinblastine—head and neck cancer	0.000932	0.00233	CcSEcCtD
Doxepin—Anorexia—Fluorouracil—head and neck cancer	0.000931	0.00233	CcSEcCtD
Doxepin—Diarrhoea—Hydroxyurea—head and neck cancer	0.000929	0.00232	CcSEcCtD
Doxepin—Eye disorder—Docetaxel—head and neck cancer	0.000928	0.00232	CcSEcCtD
Doxepin—Flushing—Docetaxel—head and neck cancer	0.000921	0.0023	CcSEcCtD
Doxepin—Cardiac disorder—Docetaxel—head and neck cancer	0.000921	0.0023	CcSEcCtD
Doxepin—Hypotension—Fluorouracil—head and neck cancer	0.000913	0.00228	CcSEcCtD
Doxepin—Angiopathy—Docetaxel—head and neck cancer	0.000901	0.00225	CcSEcCtD
Doxepin—Dizziness—Hydroxyurea—head and neck cancer	0.000898	0.00224	CcSEcCtD
Doxepin—Immune system disorder—Docetaxel—head and neck cancer	0.000897	0.00224	CcSEcCtD
Doxepin—Mediastinal disorder—Docetaxel—head and neck cancer	0.000895	0.00224	CcSEcCtD
Doxepin—Chills—Docetaxel—head and neck cancer	0.000891	0.00223	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00089	0.00222	CcSEcCtD
Doxepin—CHRM1—parotid gland—head and neck cancer	0.000888	0.021	CbGeAlD
Doxepin—Arrhythmia—Docetaxel—head and neck cancer	0.000887	0.00222	CcSEcCtD
Doxepin—Nausea—Vinblastine—head and neck cancer	0.000884	0.00221	CcSEcCtD
Doxepin—Insomnia—Fluorouracil—head and neck cancer	0.000884	0.00221	CcSEcCtD
Doxepin—Paraesthesia—Fluorouracil—head and neck cancer	0.000877	0.00219	CcSEcCtD
Doxepin—Alopecia—Docetaxel—head and neck cancer	0.000877	0.00219	CcSEcCtD
Doxepin—Dyspnoea—Fluorouracil—head and neck cancer	0.000871	0.00218	CcSEcCtD
Doxepin—Mental disorder—Docetaxel—head and neck cancer	0.00087	0.00217	CcSEcCtD
Doxepin—Somnolence—Fluorouracil—head and neck cancer	0.000869	0.00217	CcSEcCtD
Doxepin—Malnutrition—Docetaxel—head and neck cancer	0.000864	0.00216	CcSEcCtD
Doxepin—Erythema—Docetaxel—head and neck cancer	0.000864	0.00216	CcSEcCtD
Doxepin—Vomiting—Hydroxyurea—head and neck cancer	0.000863	0.00216	CcSEcCtD
Doxepin—Dyspepsia—Fluorouracil—head and neck cancer	0.00086	0.00215	CcSEcCtD
Doxepin—Rash—Hydroxyurea—head and neck cancer	0.000856	0.00214	CcSEcCtD
Doxepin—Dermatitis—Hydroxyurea—head and neck cancer	0.000855	0.00214	CcSEcCtD
Doxepin—Headache—Hydroxyurea—head and neck cancer	0.00085	0.00213	CcSEcCtD
Doxepin—CHRM1—saliva-secreting gland—head and neck cancer	0.00085	0.0201	CbGeAlD
Doxepin—Decreased appetite—Fluorouracil—head and neck cancer	0.000849	0.00212	CcSEcCtD
Doxepin—Dysgeusia—Docetaxel—head and neck cancer	0.000846	0.00211	CcSEcCtD
Doxepin—HTR6—head—head and neck cancer	0.000844	0.0199	CbGeAlD
Doxepin—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000844	0.00211	CcSEcCtD
Doxepin—Back pain—Docetaxel—head and neck cancer	0.000836	0.00209	CcSEcCtD
Doxepin—Pain—Fluorouracil—head and neck cancer	0.000836	0.00209	CcSEcCtD
Doxepin—Muscle spasms—Docetaxel—head and neck cancer	0.000831	0.00208	CcSEcCtD
Doxepin—Nausea—Hydroxyurea—head and neck cancer	0.000806	0.00201	CcSEcCtD
Doxepin—Feeling abnormal—Fluorouracil—head and neck cancer	0.000805	0.00201	CcSEcCtD
Doxepin—Anaemia—Docetaxel—head and neck cancer	0.000799	0.002	CcSEcCtD
Doxepin—Urticaria—Fluorouracil—head and neck cancer	0.000776	0.00194	CcSEcCtD
Doxepin—Syncope—Docetaxel—head and neck cancer	0.000775	0.00194	CcSEcCtD
Doxepin—Leukopenia—Docetaxel—head and neck cancer	0.000773	0.00193	CcSEcCtD
Doxepin—Body temperature increased—Fluorouracil—head and neck cancer	0.000772	0.00193	CcSEcCtD
Doxepin—HRH2—head—head and neck cancer	0.000771	0.0182	CbGeAlD
Doxepin—Palpitations—Docetaxel—head and neck cancer	0.000764	0.00191	CcSEcCtD
Doxepin—CHRM3—saliva-secreting gland—head and neck cancer	0.000761	0.018	CbGeAlD
Doxepin—Loss of consciousness—Docetaxel—head and neck cancer	0.000759	0.0019	CcSEcCtD
Doxepin—Cough—Docetaxel—head and neck cancer	0.000754	0.00188	CcSEcCtD
Doxepin—Convulsion—Docetaxel—head and neck cancer	0.000749	0.00187	CcSEcCtD
Doxepin—Hypertension—Docetaxel—head and neck cancer	0.000746	0.00186	CcSEcCtD
Doxepin—CHRM5—head—head and neck cancer	0.000737	0.0174	CbGeAlD
Doxepin—Myalgia—Docetaxel—head and neck cancer	0.000736	0.00184	CcSEcCtD
Doxepin—Arthralgia—Docetaxel—head and neck cancer	0.000736	0.00184	CcSEcCtD
Doxepin—Chest pain—Docetaxel—head and neck cancer	0.000736	0.00184	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000731	0.00183	CcSEcCtD
Doxepin—Hypersensitivity—Fluorouracil—head and neck cancer	0.00072	0.0018	CcSEcCtD
Doxepin—Dry mouth—Docetaxel—head and neck cancer	0.000719	0.0018	CcSEcCtD
Doxepin—Confusional state—Docetaxel—head and neck cancer	0.000711	0.00178	CcSEcCtD
Doxepin—Oedema—Docetaxel—head and neck cancer	0.000705	0.00176	CcSEcCtD
Doxepin—Infection—Docetaxel—head and neck cancer	0.000701	0.00175	CcSEcCtD
Doxepin—ADRA2C—parotid gland—head and neck cancer	0.000695	0.0164	CbGeAlD
Doxepin—Shock—Docetaxel—head and neck cancer	0.000694	0.00173	CcSEcCtD
Doxepin—Nervous system disorder—Docetaxel—head and neck cancer	0.000692	0.00173	CcSEcCtD
Doxepin—Pruritus—Fluorouracil—head and neck cancer	0.000691	0.00173	CcSEcCtD
Doxepin—Thrombocytopenia—Docetaxel—head and neck cancer	0.00069	0.00173	CcSEcCtD
Doxepin—Tachycardia—Docetaxel—head and neck cancer	0.000688	0.00172	CcSEcCtD
Doxepin—Skin disorder—Docetaxel—head and neck cancer	0.000685	0.00171	CcSEcCtD
Doxepin—ADRA1B—head—head and neck cancer	0.000673	0.0159	CbGeAlD
Doxepin—Anorexia—Docetaxel—head and neck cancer	0.000672	0.00168	CcSEcCtD
Doxepin—Diarrhoea—Fluorouracil—head and neck cancer	0.000669	0.00167	CcSEcCtD
Doxepin—Hypotension—Docetaxel—head and neck cancer	0.000659	0.00165	CcSEcCtD
Doxepin—ADRA1D—head—head and neck cancer	0.000659	0.0156	CbGeAlD
Doxepin—CHRM1—trachea—head and neck cancer	0.000656	0.0155	CbGeAlD
Doxepin—Dizziness—Fluorouracil—head and neck cancer	0.000646	0.00161	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000643	0.00161	CcSEcCtD
Doxepin—Insomnia—Docetaxel—head and neck cancer	0.000638	0.00159	CcSEcCtD
Doxepin—Paraesthesia—Docetaxel—head and neck cancer	0.000633	0.00158	CcSEcCtD
Doxepin—Dyspnoea—Docetaxel—head and neck cancer	0.000629	0.00157	CcSEcCtD
Doxepin—Somnolence—Docetaxel—head and neck cancer	0.000627	0.00157	CcSEcCtD
Doxepin—Vomiting—Fluorouracil—head and neck cancer	0.000621	0.00155	CcSEcCtD
Doxepin—Dyspepsia—Docetaxel—head and neck cancer	0.000621	0.00155	CcSEcCtD
Doxepin—Rash—Fluorouracil—head and neck cancer	0.000616	0.00154	CcSEcCtD
Doxepin—Dermatitis—Fluorouracil—head and neck cancer	0.000615	0.00154	CcSEcCtD
Doxepin—Decreased appetite—Docetaxel—head and neck cancer	0.000613	0.00153	CcSEcCtD
Doxepin—Headache—Fluorouracil—head and neck cancer	0.000612	0.00153	CcSEcCtD
Doxepin—ADRA1A—epithelium—head and neck cancer	0.000609	0.0144	CbGeAlD
Doxepin—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000609	0.00152	CcSEcCtD
Doxepin—Fatigue—Docetaxel—head and neck cancer	0.000608	0.00152	CcSEcCtD
Doxepin—Constipation—Docetaxel—head and neck cancer	0.000603	0.00151	CcSEcCtD
Doxepin—Pain—Docetaxel—head and neck cancer	0.000603	0.00151	CcSEcCtD
Doxepin—Feeling abnormal—Docetaxel—head and neck cancer	0.000581	0.00145	CcSEcCtD
Doxepin—Nausea—Fluorouracil—head and neck cancer	0.00058	0.00145	CcSEcCtD
Doxepin—HTR2A—neck—head and neck cancer	0.000579	0.0137	CbGeAlD
Doxepin—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000577	0.00144	CcSEcCtD
Doxepin—Abdominal pain—Docetaxel—head and neck cancer	0.000557	0.00139	CcSEcCtD
Doxepin—Body temperature increased—Docetaxel—head and neck cancer	0.000557	0.00139	CcSEcCtD
Doxepin—HRH2—lymph node—head and neck cancer	0.00054	0.0128	CbGeAlD
Doxepin—Hypersensitivity—Docetaxel—head and neck cancer	0.00052	0.0013	CcSEcCtD
Doxepin—HTR2B—thyroid gland—head and neck cancer	0.000516	0.0122	CbGeAlD
Doxepin—ADRA2C—trachea—head and neck cancer	0.000514	0.0121	CbGeAlD
Doxepin—Asthenia—Docetaxel—head and neck cancer	0.000506	0.00126	CcSEcCtD
Doxepin—CHRM2—head—head and neck cancer	0.000506	0.0119	CbGeAlD
Doxepin—Pruritus—Docetaxel—head and neck cancer	0.000499	0.00125	CcSEcCtD
Doxepin—HRH1—connective tissue—head and neck cancer	0.000497	0.0117	CbGeAlD
Doxepin—ADRA2A—connective tissue—head and neck cancer	0.000488	0.0115	CbGeAlD
Doxepin—HTR2C—head—head and neck cancer	0.000487	0.0115	CbGeAlD
Doxepin—Diarrhoea—Docetaxel—head and neck cancer	0.000483	0.00121	CcSEcCtD
Doxepin—HRH1—epithelium—head and neck cancer	0.000472	0.0111	CbGeAlD
Doxepin—ADRA1A—lymphoid tissue—head and neck cancer	0.000469	0.0111	CbGeAlD
Doxepin—Dizziness—Docetaxel—head and neck cancer	0.000466	0.00117	CcSEcCtD
Doxepin—CHRM3—thyroid gland—head and neck cancer	0.000464	0.011	CbGeAlD
Doxepin—SLC6A4—head—head and neck cancer	0.000462	0.0109	CbGeAlD
Doxepin—CHRM1—head—head and neck cancer	0.00046	0.0109	CbGeAlD
Doxepin—HTR2B—head—head and neck cancer	0.000458	0.0108	CbGeAlD
Doxepin—Vomiting—Docetaxel—head and neck cancer	0.000448	0.00112	CcSEcCtD
Doxepin—Rash—Docetaxel—head and neck cancer	0.000445	0.00111	CcSEcCtD
Doxepin—Dermatitis—Docetaxel—head and neck cancer	0.000444	0.00111	CcSEcCtD
Doxepin—Headache—Docetaxel—head and neck cancer	0.000442	0.0011	CcSEcCtD
Doxepin—Nausea—Docetaxel—head and neck cancer	0.000419	0.00105	CcSEcCtD
Doxepin—HRH1—trachea—head and neck cancer	0.000417	0.00986	CbGeAlD
Doxepin—HTR2A—connective tissue—head and neck cancer	0.000415	0.0098	CbGeAlD
Doxepin—CHRM3—head—head and neck cancer	0.000412	0.00973	CbGeAlD
Doxepin—HTR1A—head—head and neck cancer	0.00041	0.00969	CbGeAlD
Doxepin—ADRA2A—trachea—head and neck cancer	0.00041	0.00968	CbGeAlD
Doxepin—SLC6A2—head—head and neck cancer	0.000407	0.00961	CbGeAlD
Doxepin—HTR2A—epithelium—head and neck cancer	0.000394	0.00931	CbGeAlD
Doxepin—ORM1—lymph node—head and neck cancer	0.00038	0.00897	CbGeAlD
Doxepin—ADRA1A—head—head and neck cancer	0.000378	0.00894	CbGeAlD
Doxepin—DRD2—head—head and neck cancer	0.000371	0.00876	CbGeAlD
Doxepin—KCNH2—head—head and neck cancer	0.000365	0.00863	CbGeAlD
Doxepin—ADRA2C—head—head and neck cancer	0.00036	0.00851	CbGeAlD
Doxepin—CYP1A2—thyroid gland—head and neck cancer	0.000353	0.00833	CbGeAlD
Doxepin—HTR2A—trachea—head and neck cancer	0.000348	0.00823	CbGeAlD
Doxepin—ADRA2A—thyroid gland—head and neck cancer	0.000324	0.00766	CbGeAlD
Doxepin—HTR2B—lymph node—head and neck cancer	0.000321	0.00757	CbGeAlD
Doxepin—HRH1—head—head and neck cancer	0.000293	0.00692	CbGeAlD
Doxepin—ADRA2A—head—head and neck cancer	0.000288	0.00679	CbGeAlD
Doxepin—SLC6A2—lymph node—head and neck cancer	0.000285	0.00673	CbGeAlD
Doxepin—ABCB1—epithelium—head and neck cancer	0.000258	0.0061	CbGeAlD
Doxepin—KCNH2—lymph node—head and neck cancer	0.000256	0.00604	CbGeAlD
Doxepin—ADRA2C—lymph node—head and neck cancer	0.000252	0.00596	CbGeAlD
Doxepin—HTR2A—head—head and neck cancer	0.000245	0.00578	CbGeAlD
Doxepin—ABCB1—trachea—head and neck cancer	0.000228	0.00539	CbGeAlD
Doxepin—CYP2D6—head—head and neck cancer	0.000223	0.00526	CbGeAlD
Doxepin—HRH1—lymph node—head and neck cancer	0.000205	0.00484	CbGeAlD
Doxepin—ADRA2A—lymph node—head and neck cancer	0.000201	0.00476	CbGeAlD
Doxepin—ABCB1—lymphoid tissue—head and neck cancer	0.000199	0.0047	CbGeAlD
Doxepin—ABCB1—thyroid gland—head and neck cancer	0.000181	0.00427	CbGeAlD
Doxepin—ABCB1—head—head and neck cancer	0.00016	0.00379	CbGeAlD
Doxepin—ABCB1—lymph node—head and neck cancer	0.000112	0.00265	CbGeAlD
Doxepin—CHRM3—Metabolism—PTEN—head and neck cancer	2.04e-05	0.000114	CbGpPWpGaD
Doxepin—ADRA1B—GPCR downstream signaling—AKT1—head and neck cancer	2.04e-05	0.000113	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—PIK3CA—head and neck cancer	2.04e-05	0.000113	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—AKT1—head and neck cancer	2.02e-05	0.000112	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—PIK3CA—head and neck cancer	2.02e-05	0.000112	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—IL2—head and neck cancer	2.02e-05	0.000112	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—GPX1—head and neck cancer	2.01e-05	0.000112	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—AKT1—head and neck cancer	2.01e-05	0.000112	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—PIK3CA—head and neck cancer	2.01e-05	0.000112	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—CCND1—head and neck cancer	2e-05	0.000111	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—MAPK1—head and neck cancer	2e-05	0.000111	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—EGFR—head and neck cancer	2e-05	0.000111	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.99e-05	0.000111	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—PTEN—head and neck cancer	1.99e-05	0.000111	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—PTEN—head and neck cancer	1.98e-05	0.00011	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—MAPK1—head and neck cancer	1.98e-05	0.00011	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—EGFR—head and neck cancer	1.98e-05	0.00011	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—CCND1—head and neck cancer	1.96e-05	0.000109	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—MAPK3—head and neck cancer	1.95e-05	0.000109	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—AKT1—head and neck cancer	1.94e-05	0.000108	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	1.93e-05	0.000108	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—HRAS—head and neck cancer	1.93e-05	0.000108	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—PTEN—head and neck cancer	1.93e-05	0.000107	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.92e-05	0.000107	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	1.9e-05	0.000106	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—PIK3CA—head and neck cancer	1.9e-05	0.000106	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—HRAS—head and neck cancer	1.9e-05	0.000106	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—PTEN—head and neck cancer	1.9e-05	0.000106	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—HRAS—head and neck cancer	1.89e-05	0.000105	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—HRAS—head and neck cancer	1.88e-05	0.000105	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—AKT1—head and neck cancer	1.88e-05	0.000105	CbGpPWpGaD
Doxepin—DRD2—GPCR downstream signaling—AKT1—head and neck cancer	1.88e-05	0.000105	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—PTEN—head and neck cancer	1.87e-05	0.000104	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—PIK3CA—head and neck cancer	1.87e-05	0.000104	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—HRAS—head and neck cancer	1.87e-05	0.000104	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—VEGFA—head and neck cancer	1.86e-05	0.000104	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—HRAS—head and neck cancer	1.86e-05	0.000104	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—IL2—head and neck cancer	1.86e-05	0.000103	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—MAPK1—head and neck cancer	1.86e-05	0.000103	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—EGFR—head and neck cancer	1.86e-05	0.000103	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—AKT1—head and neck cancer	1.85e-05	0.000103	CbGpPWpGaD
Doxepin—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	1.85e-05	0.000103	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—STAT3—head and neck cancer	1.84e-05	0.000103	CbGpPWpGaD
Doxepin—HRH1—GPCR downstream signaling—AKT1—head and neck cancer	1.84e-05	0.000103	CbGpPWpGaD
Doxepin—CHRM1—GPCR downstream signaling—AKT1—head and neck cancer	1.84e-05	0.000102	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—TP53—head and neck cancer	1.84e-05	0.000102	CbGpPWpGaD
Doxepin—CHRM3—GPCR downstream signaling—AKT1—head and neck cancer	1.83e-05	0.000102	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—IL2—head and neck cancer	1.83e-05	0.000102	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—IL2—head and neck cancer	1.82e-05	0.000102	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—IL2—head and neck cancer	1.82e-05	0.000101	CbGpPWpGaD
Doxepin—CHRM2—GPCR downstream signaling—AKT1—head and neck cancer	1.81e-05	0.000101	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—IL2—head and neck cancer	1.81e-05	0.000101	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—CCND1—head and neck cancer	1.81e-05	0.000101	CbGpPWpGaD
Doxepin—ADRA1A—GPCR downstream signaling—AKT1—head and neck cancer	1.81e-05	0.000101	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—VEGFA—head and neck cancer	1.8e-05	0.0001	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—IL2—head and neck cancer	1.8e-05	9.99e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—IL2—head and neck cancer	1.79e-05	9.96e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—PIK3CA—head and neck cancer	1.79e-05	9.96e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	1.79e-05	9.96e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—CCND1—head and neck cancer	1.78e-05	9.92e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—STAT3—head and neck cancer	1.78e-05	9.91e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—CCND1—head and neck cancer	1.78e-05	9.9e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—CCND1—head and neck cancer	1.77e-05	9.87e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—STAT3—head and neck cancer	1.77e-05	9.86e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—CCND1—head and neck cancer	1.77e-05	9.83e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—MAPK3—head and neck cancer	1.76e-05	9.81e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—HRAS—head and neck cancer	1.76e-05	9.77e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—CCND1—head and neck cancer	1.75e-05	9.74e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—PTEN—head and neck cancer	1.75e-05	9.73e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—CCND1—head and neck cancer	1.75e-05	9.71e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—VEGFA—head and neck cancer	1.74e-05	9.69e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—PIK3CA—head and neck cancer	1.73e-05	9.64e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—TP53—head and neck cancer	1.73e-05	9.64e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—HRAS—head and neck cancer	1.73e-05	9.62e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—STAT3—head and neck cancer	1.72e-05	9.59e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—PTEN—head and neck cancer	1.72e-05	9.57e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—PTEN—head and neck cancer	1.72e-05	9.55e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—PIK3CA—head and neck cancer	1.71e-05	9.54e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—VEGFA—head and neck cancer	1.71e-05	9.53e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—PTEN—head and neck cancer	1.71e-05	9.52e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—AKT1—head and neck cancer	1.71e-05	9.49e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—PTEN—head and neck cancer	1.71e-05	9.49e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—MAPK3—head and neck cancer	1.7e-05	9.47e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—STAT3—head and neck cancer	1.7e-05	9.44e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	1.69e-05	9.42e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—PTEN—head and neck cancer	1.69e-05	9.4e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—PTEN—head and neck cancer	1.68e-05	9.37e-05	CbGpPWpGaD
Doxepin—ADRA2A—GPCR downstream signaling—AKT1—head and neck cancer	1.68e-05	9.36e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	1.68e-05	9.34e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—MAPK1—head and neck cancer	1.68e-05	9.33e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—EGFR—head and neck cancer	1.68e-05	9.33e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—TP53—head and neck cancer	1.68e-05	9.33e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—AKT1—head and neck cancer	1.67e-05	9.32e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—AKT1—head and neck cancer	1.67e-05	9.29e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—AKT1—head and neck cancer	1.66e-05	9.26e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IL2—head and neck cancer	1.66e-05	9.26e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—TP53—head and neck cancer	1.66e-05	9.23e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—HRAS—head and neck cancer	1.66e-05	9.22e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—AKT1—head and neck cancer	1.65e-05	9.17e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—MAPK3—head and neck cancer	1.65e-05	9.16e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—AKT1—head and neck cancer	1.64e-05	9.15e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—TYMS—head and neck cancer	1.64e-05	9.13e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.64e-05	9.11e-05	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—PIK3CA—head and neck cancer	1.63e-05	9.05e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.62e-05	9.03e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CCND1—head and neck cancer	1.62e-05	9.02e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—MAPK3—head and neck cancer	1.62e-05	9.02e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—MAPK1—head and neck cancer	1.62e-05	9.01e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—EGFR—head and neck cancer	1.62e-05	9.01e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—PIK3CA—head and neck cancer	1.61e-05	8.97e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	1.61e-05	8.96e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—EGFR—head and neck cancer	1.61e-05	8.96e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—HRAS—head and neck cancer	1.6e-05	8.92e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—HRAS—head and neck cancer	1.59e-05	8.83e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—VEGFA—head and neck cancer	1.58e-05	8.79e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—MAPK1—head and neck cancer	1.57e-05	8.72e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—EGFR—head and neck cancer	1.57e-05	8.72e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—PTEN—head and neck cancer	1.57e-05	8.71e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—STAT3—head and neck cancer	1.56e-05	8.7e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—TP53—head and neck cancer	1.56e-05	8.68e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	1.55e-05	8.65e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—GPX1—head and neck cancer	1.55e-05	8.64e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—VEGFA—head and neck cancer	1.55e-05	8.63e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—AKT1—head and neck cancer	1.55e-05	8.63e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—VEGFA—head and neck cancer	1.55e-05	8.6e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—MAPK1—head and neck cancer	1.54e-05	8.58e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—EGFR—head and neck cancer	1.54e-05	8.58e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—VEGFA—head and neck cancer	1.54e-05	8.57e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—STAT3—head and neck cancer	1.54e-05	8.56e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.54e-05	8.56e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—STAT3—head and neck cancer	1.54e-05	8.54e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—STAT3—head and neck cancer	1.53e-05	8.52e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—AKT1—head and neck cancer	1.53e-05	8.5e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—VEGFA—head and neck cancer	1.53e-05	8.49e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—STAT3—head and neck cancer	1.53e-05	8.49e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—VEGFA—head and neck cancer	1.52e-05	8.47e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PTGS2—head and neck cancer	1.52e-05	8.46e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—STAT3—head and neck cancer	1.51e-05	8.41e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—STAT3—head and neck cancer	1.51e-05	8.38e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—MAPK3—head and neck cancer	1.49e-05	8.31e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—HRAS—head and neck cancer	1.49e-05	8.3e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PTGS2—head and neck cancer	1.48e-05	8.26e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	1.47e-05	8.18e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—MAPK3—head and neck cancer	1.47e-05	8.16e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—AKT1—head and neck cancer	1.46e-05	8.14e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—MAPK3—head and neck cancer	1.46e-05	8.14e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—MAPK3—head and neck cancer	1.46e-05	8.11e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—PIK3CA—head and neck cancer	1.46e-05	8.1e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MAPK3—head and neck cancer	1.44e-05	8.03e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MAPK3—head and neck cancer	1.44e-05	8.01e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—PIK3CA—head and neck cancer	1.44e-05	8.01e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—MAPK1—head and neck cancer	1.42e-05	7.91e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—EGFR—head and neck cancer	1.42e-05	7.91e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—AKT1—head and neck cancer	1.42e-05	7.88e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—VEGFA—head and neck cancer	1.41e-05	7.87e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—TP53—head and neck cancer	1.41e-05	7.84e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—PIK3CA—head and neck cancer	1.4e-05	7.82e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—AKT1—head and neck cancer	1.4e-05	7.79e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—STAT3—head and neck cancer	1.4e-05	7.79e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	1.4e-05	7.78e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PTGS2—head and neck cancer	1.4e-05	7.78e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—EGFR—head and neck cancer	1.4e-05	7.78e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	1.4e-05	7.78e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—MAPK1—head and neck cancer	1.4e-05	7.77e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—EGFR—head and neck cancer	1.4e-05	7.77e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—MAPK1—head and neck cancer	1.39e-05	7.74e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—EGFR—head and neck cancer	1.39e-05	7.74e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—MAPK1—head and neck cancer	1.39e-05	7.72e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PTGS2—head and neck cancer	1.39e-05	7.72e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—EGFR—head and neck cancer	1.39e-05	7.72e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MAPK1—head and neck cancer	1.37e-05	7.64e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—EGFR—head and neck cancer	1.37e-05	7.64e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MAPK1—head and neck cancer	1.37e-05	7.62e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—EGFR—head and neck cancer	1.37e-05	7.62e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—PIK3CA—head and neck cancer	1.36e-05	7.57e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—TP53—head and neck cancer	1.36e-05	7.56e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—TP53—head and neck cancer	1.35e-05	7.52e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—HRAS—head and neck cancer	1.35e-05	7.49e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—PIK3CA—head and neck cancer	1.34e-05	7.45e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MAPK3—head and neck cancer	1.34e-05	7.44e-05	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—AKT1—head and neck cancer	1.33e-05	7.39e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PTEN—head and neck cancer	1.33e-05	7.38e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—PIK3CA—head and neck cancer	1.32e-05	7.35e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—AKT1—head and neck cancer	1.32e-05	7.33e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—TP53—head and neck cancer	1.32e-05	7.32e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—HRAS—head and neck cancer	1.3e-05	7.23e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PTEN—head and neck cancer	1.29e-05	7.2e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—TP53—head and neck cancer	1.29e-05	7.2e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—HRAS—head and neck cancer	1.29e-05	7.2e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MAPK1—head and neck cancer	1.27e-05	7.08e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—EGFR—head and neck cancer	1.27e-05	7.08e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—HRAS—head and neck cancer	1.26e-05	7e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—HRAS—head and neck cancer	1.24e-05	6.89e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—PIK3CA—head and neck cancer	1.23e-05	6.86e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PTEN—head and neck cancer	1.22e-05	6.79e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	1.21e-05	6.75e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—PIK3CA—head and neck cancer	1.21e-05	6.74e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PTEN—head and neck cancer	1.21e-05	6.73e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—PIK3CA—head and neck cancer	1.21e-05	6.72e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—PIK3CA—head and neck cancer	1.2e-05	6.7e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—TP53—head and neck cancer	1.19e-05	6.64e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—PIK3CA—head and neck cancer	1.19e-05	6.63e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—AKT1—head and neck cancer	1.19e-05	6.62e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—PIK3CA—head and neck cancer	1.19e-05	6.61e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PTGS2—head and neck cancer	1.18e-05	6.59e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—AKT1—head and neck cancer	1.18e-05	6.54e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—TP53—head and neck cancer	1.17e-05	6.53e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—TP53—head and neck cancer	1.17e-05	6.52e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—TP53—head and neck cancer	1.17e-05	6.5e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—TP53—head and neck cancer	1.16e-05	6.48e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—TP53—head and neck cancer	1.15e-05	6.42e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—TP53—head and neck cancer	1.15e-05	6.4e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—AKT1—head and neck cancer	1.15e-05	6.39e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—AKT1—head and neck cancer	1.14e-05	6.35e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—HRAS—head and neck cancer	1.14e-05	6.35e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—HRAS—head and neck cancer	1.12e-05	6.25e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—HRAS—head and neck cancer	1.12e-05	6.24e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—HRAS—head and neck cancer	1.12e-05	6.22e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—HRAS—head and neck cancer	1.11e-05	6.2e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—AKT1—head and neck cancer	1.11e-05	6.18e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—PIK3CA—head and neck cancer	1.1e-05	6.14e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—HRAS—head and neck cancer	1.1e-05	6.14e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—HRAS—head and neck cancer	1.1e-05	6.12e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—AKT1—head and neck cancer	1.09e-05	6.08e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—AKT1—head and neck cancer	1.08e-05	6e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—TP53—head and neck cancer	1.07e-05	5.94e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PTEN—head and neck cancer	1.03e-05	5.75e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—HRAS—head and neck cancer	1.02e-05	5.69e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—AKT1—head and neck cancer	1.01e-05	5.61e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—AKT1—head and neck cancer	9.91e-06	5.52e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—AKT1—head and neck cancer	9.89e-06	5.51e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—AKT1—head and neck cancer	9.86e-06	5.49e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—AKT1—head and neck cancer	9.83e-06	5.47e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—AKT1—head and neck cancer	9.73e-06	5.42e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—AKT1—head and neck cancer	9.71e-06	5.4e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PIK3CA—head and neck cancer	9.36e-06	5.21e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PTGS2—head and neck cancer	9.14e-06	5.09e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PIK3CA—head and neck cancer	9.13e-06	5.08e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—AKT1—head and neck cancer	9.02e-06	5.02e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CA—head and neck cancer	8.6e-06	4.79e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CA—head and neck cancer	8.53e-06	4.75e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PTEN—head and neck cancer	7.97e-06	4.44e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—AKT1—head and neck cancer	7.64e-06	4.25e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—AKT1—head and neck cancer	7.46e-06	4.15e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CA—head and neck cancer	7.29e-06	4.06e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—AKT1—head and neck cancer	7.03e-06	3.91e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—AKT1—head and neck cancer	6.97e-06	3.88e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—AKT1—head and neck cancer	5.95e-06	3.31e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CA—head and neck cancer	5.63e-06	3.13e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—AKT1—head and neck cancer	4.6e-06	2.56e-05	CbGpPWpGaD
